Amylase‐producing IgD‐type multiple myeloma

Delannoy, André; Hamels, J.; Mecucci, Cristina; Fally, P.; Wallef, G; Fooz, C. De; Carlier, B.

doi:10.1111/j.1365-2796.1992.tb00615.x

Cited by 24 publications

(15 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…lO Natazuka et al 11 Fujii et al 12 Moriyama et al 13 Moriyama at al. 13 Delannoy et al 14 Lopez et al 15 Hirota et al 16 Yamakawa et alY Nakajima et al 18 Bloemendal and Lobatto19 Nair et al 2O creatinine clearance ratio and the polyethylene glycol precipitation of <13%.…”

Section: Discussionmentioning

confidence: 99%

Hyperamylasaemia and multiple myeloma

Ross¹,

Devgun²,

Gunn³

2002

Annals of Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Hyperamylasaemia and multiple myeloma

Ross¹,

Devgun²,

Gunn³

2002

Annals of Clinical Biochemistry

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6] Recently, a few new clinical features associated with myeloma, such as salivary type hyperamylasemia [7][8][9][10][11][12][13] and elevation of the serum Creactive protein (CRP) concentration [14][15][16] and oncostatin M, 17 have been reported. Elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of the identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells.…”

Section: Introductionmentioning

confidence: 99%

In vitro excess ammonia production in human myeloma cell lines

et al. 1998

View full text Add to dashboard Cite

It is well known that cases with multiple myeloma reveal various clinical manifestations such as pancytopenia, hyperproteinemia, renal dysfunction, bone lesions, hypercalcemia and immunodeficiency. Recently, a few more clinical features associated with myeloma, such as salivary type hyperamylasemia and elevated serum C-reactive protein (CRP) concentration, have been reported. The elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells. More recently, there have been several reports of cases with myeloma associated with hyperammonemia. This hyperammonemia is not considered to be due to liver dysfunction, because in most of these cases tests revealed normal hepatic function, and some cases showed different patterns of serum amino acid distribution than that associated with hepatic failure. However, there have been no apparent observations of ammonia production by myeloma cells. In this study, we used six human myeloma cell lines including KMS-18, which was recently established from a myeloma case associated with hyperammonemia. These lines were treated with MRA (mycoplasma removal agent) to observe ammonia production in vitro. They produced and released significantly higher levels of ammonia into culture medium than non-myeloma hematological cell lines or the HepG2 human hepatic carcinoma cell line. Although attempts to analyze the relative expression levels of the enzymes related to ammonia biosynthesis using the reverse transcriptase-polymerase chain reaction assay failed to detect any differences between these myeloma lines and other cell lines, in vitro excess ammonia production by the myeloma cells was confirmed and the relevance to clinical manifestations is discussed.

show abstract

“…The association between malignancy and hyperamylasaemia was first described in a patient with lung cancer in 1951 [3]. Subsequently, an increased ectopic production of amylase has been reported in both epithelial and non-epithelial tumors [4,5,6]. The present report describes a fatal case of a patient presenting marked hyperamylasaemia which appeared at diagnosis and with the relapse of an underlying multiple myeloma.…”

Section: Introductionmentioning

confidence: 87%

“…Occasional reports, mostly from Japan, have documented this rare complication in a few cases of multiple myeloma with extramedullary spread [4,5,6,7,8,9,10,11,12,13,14]. Currently, pathogenesis of the hyperamylasaemia-associated myeloma is not well understood [4, 5].…”

Section: Discussionmentioning

confidence: 99%

Paraneoplastic Hyperamylasaemia in Association with Multiple Myeloma

Calvo-Villas¹,

Alvarez²,

Carretera³

et al. 2007

Acta Haematol

View full text Add to dashboard Cite

Marked hyperamylasaemia associated with an amylase-producing multiple myeloma appears to be a fairly unusual phenomenon. The present report describes a fatal case of multiple myeloma associated with paraneoplastic hyperamylasaemia without evidence of pancreatic or salivary gland involvement. Serum and urine amylase levels paralleled the myeloma response to chemotherapy and disease progression. The importance of paraneoplastic hyperamylasaemia as a useful myeloma marker to monitor disease progression and treatment response is emphasized. Conventional chemotherapy at diagnosis and salvage treatment with bortezomib at relapse failed to achieve a long-term response and to decrease the serum amylase to a normal level.

show abstract

Amylase‐producing IgD‐type multiple myeloma

Cited by 24 publications

References 7 publications

Hyperamylasaemia and multiple myeloma

Hyperamylasaemia and multiple myeloma

In vitro excess ammonia production in human myeloma cell lines

Paraneoplastic Hyperamylasaemia in Association with Multiple Myeloma

Contact Info

Product

Resources

About